Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$32.52 +2.00%

+$0.69 today

Market cap
$6.73B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.73M

Average 1.84M

Balance Sheet

Inspect the capital base behind the business.

Assets

$957.57M

FY 2026 · Annual

+23.4% YoY

Liabilities

$104.97M

FY 2026 · Annual

+52.6% YoY

Equity

$852.59M

FY 2026 · Annual

+20.5% YoY

Balance Sheet

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Cash & Equivalents493.82M376.53M635.37M713.97M902.11M
Short-term Investments00000
Net Receivables12.86M885K5.5M2.51M3.95M
Inventory00000
Other Current Assets0024.9M51.18M42.76M
Total Current Assets512.93M404.33M665.77M767.66M948.82M
Property, Plant & Equipment (Net)2.63M1.51M595K942K515K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00347K0553K
Other Non-current Assets0007.62M7.68M
Total Non-current Assets2.63M1.51M942K8.56M8.75M
Total Assets515.56M405.84M666.71M776.22M957.57M
Account Payables18.63M1.35M7.16M17.66M7.54M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities171K350K14.74M15.62M16.77M
Total Current Liabilities44.52M43.3M48.61M68.78M104.42M
Long-term Debt00000
Deferred Tax Liabilities00347K0553K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities1.22M47K347K0553K
Total Liabilities45.74M43.34M48.96M68.78M104.98M
Common Stock12K13K14K16K20K
Retained Earnings(355.39M)(566.35M)(825.68M)(1.24B)(1.75B)
Accumulated OCI404K852K1.91M1.46M730K
Other Stockholders Equity00000
Minority Interest00000
Total Equity469.83M362.49M617.76M707.45M852.59M
Total Debt2.36M1.22M138K98K72K
Net Debt(491.45M)(375.31M)(635.23M)(713.87M)(902.04M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$722.3M
Receivables$138.0K
Other Current$37.6M
Total Current Assets$760.0M
PP&E (Net)$262.0K
Other Non-current$659.0K
Total Non-current Assets$921.0K
Total Assets$761.0M

Analysis

Selected assets total $761.0M for Latest. The largest visible component is Cash & Equivalents at $722.3M, about 94.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
S-3ASRS-3ASR filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

How much cash does IMVT have?

Immunovant, Inc. (IMVT) reported $902.11M in cash and equivalents in fiscal 2026.

How much debt does IMVT carry?

Immunovant, Inc. (IMVT) reported $72,000.00 of total debt, with net debt of -$902.04M.